{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:27:34Z","timestamp":1777649254393,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.canlet.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T19:00:13Z","timestamp":1412881213000},"page":"597-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"PB","title":["MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR\u2013ABL protein"],"prefix":"10.1016","volume":"356","author":[{"given":"Oshrat","family":"Hershkovitz-Rokah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shira","family":"Modai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metsada","family":"Pasmanik-Chor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amos","family":"Toren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Shomron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galit","family":"Granot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.10.006_bib0010","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.10.006_bib0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2013a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.10.006_bib0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.04.040","article-title":"SnapShot: MicroRNAs in Cancer","volume":"137","author":"Spizzo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.10.006_bib0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.leukres.2005.09.001","article-title":"Hematopoietic-specific microRNA expression in human cells","volume":"30","author":"Ramkissoon","year":"2006","journal-title":"Leuk. Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0030","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2014.10.006_bib0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr2484","article-title":"MicroRNAs and their target gene networks in breast cancer","volume":"12","author":"O'Day","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1556-0864(15)31623-3","article-title":"MicroRNA in lung cancer","volume":"1","author":"Nana-Sinkam","year":"2006","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.canlet.2014.10.006_bib0045","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.22757","article-title":"MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma","volume":"49","author":"Li","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2014.10.006_bib0050","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1016\/j.ejca.2010.06.127","article-title":"MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells","volume":"46","author":"Xu","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2014.10.006_bib0055","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1158\/0008-5472.CAN-05-0137","article-title":"MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells","volume":"65","author":"Chan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-4598-5-29","article-title":"Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues","volume":"5","author":"Bandres","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2014.10.006_bib0065","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/sj.onc.1210186","article-title":"MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia","volume":"26","author":"Garzon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.10.006_bib0070","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1590\/S0100-879X2007001100003","article-title":"miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia","volume":"40","author":"Zanette","year":"2007","journal-title":"Braz. J. Med. Biol. Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0075","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.10.006_bib0080","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.yexcr.2013.02.002","article-title":"miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR\/ABL1 protein","volume":"319","author":"Li","year":"2013","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/onc.2012.557","article-title":"BCR-ABL\/GATA1\/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia","volume":"33","author":"Xu","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.10.006_bib0090","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth","volume":"6","author":"Agirre","year":"2008","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12079-011-0139-x","article-title":"MicroRNAs 130a\/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML","volume":"5","author":"Suresh","year":"2011","journal-title":"J. Cell Commun. Signal"},{"key":"10.1016\/j.canlet.2014.10.006_bib0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","author":"Liu","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0105","article-title":"Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells","volume":"7","author":"Rokah","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2014.10.006_bib0110","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2014.10.006_bib0115","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.10.006_bib0120","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1002\/cncr.28328","article-title":"Tolerability and efficacy of pegylated interferon-alpha-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia","volume":"119","author":"Johnson-Ansah","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.10.006_bib0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.leukres.2013.01.021","article-title":"Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors","volume":"37","author":"Breccia","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2014.10.006_bib0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2012.03.021","article-title":"How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages","volume":"322","author":"Breccia","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2014.10.006_bib0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","article-title":"High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients \u2013 systematic review and meta-analysis","volume":"86","author":"Gafter-Gvili","year":"2011","journal-title":"Am. J. Hematol"},{"key":"10.1016\/j.canlet.2014.10.006_bib0145","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.10.006_bib0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00063030-200923010-00002","article-title":"MicroRNA-based therapeutics for cancer","volume":"23","author":"Wang","year":"2009","journal-title":"Biodrugs"},{"key":"10.1016\/j.canlet.2014.10.006_bib0155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.10.006_bib0160","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17\u201392 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","author":"Venturini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.10.006_bib0165","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1158\/0008-5472.CAN-05-4154","article-title":"High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma","volume":"66","author":"Stallings","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.006_bib0170","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1038\/onc.2010.167","article-title":"Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells","volume":"29","author":"Yu","year":"2010","journal-title":"Oncogene"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514005941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514005941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T17:19:55Z","timestamp":1598375995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514005941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0304383514005941"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.10.006","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR\u2013ABL protein","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}